

A new *Plasmodium falciparum* field isolate from Benin in continuous culture: Infectivity of fresh-produced and cryopreserved gametocytes to *Anopheles gambiae*

Adandé A. Medjigbodo

Université d'Abomey-Calavi

Festus K. Acquah

University of Ghana

Laurette Djossou

Université d'Abomey-Calavi

Linda E. Amoah

University of Ghana

Edgard-Marius Ouendo

Université d'Abomey-Calavi

David Weetman

Liverpool School of Tropical Medicine

Martin J. Donnelly

Liverpool School of Tropical Medicine

Luc S. Djogbenou (✉ luc.djogbenou@lstmed.ac.uk)

Université d'Abomey-Calavi

Research Article

Keywords: parasites, *Plasmodium falciparum*, infectivity, cryopreserved gametocytes, Benin

Posted Date: March 3rd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-255706/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Transmission-blocking vaccines and drugs are likely to be key interventions in efforts to achieve malaria elimination. However, transmission-blocking studies are reliant upon a limited number of culture-adapted strains of *Plasmodium falciparum* with limited genetic variability, or on field isolates which are only maintained transiently in the laboratory and therefore not amenable to replication studies. Herein, we investigated the gametocytogenesis capacity and infectivity to *Anopheles gambiae* mosquitoes of a *P. falciparum* field isolate collected from a malaria patient from Benin compared to those of NF54 strain. The intraerythrocytic developmental cycle (IDC) was similar in both *P. falciparum* strains (ranges of parasitaemias were respectively 0.02–11.53% and 0.035–10.5% throughout twelve days of culture). The culture-adapted parasites displayed a significant higher infectivity to *An. gambiae* compared to that of NF54 (mean oocyst prevalence and intensity: 16.94%, $CI_{95\%} = [15.15–18.73]$ vs. 3.13%, $CI_{95\%} = [2.30–3.96]$, $p < 0.0001$ and 3 vs. 1 oocysts/infected mosquito, $p = 0.002$ respectively). Even after cryopreservation for up to 14 days, gametocytes from the field isolates were capable of infecting *An. gambiae* mosquitoes at a prevalence of up to 30% with an average of 12 oocysts/ midgut. This new *P. falciparum* strain will enhance malaria transmission-blocking studies in endemic countries.

Background

Since the beginning of the twenty-first century, substantial strides in malaria control have been made through the use of long-lasting insecticide-treated bed nets (LLINs), indoor residual-insecticide spraying (IRS) and artemisinin-based combination therapies (ACTs) ¹. However, as insecticide-based interventions have been scaled-up, a concomitant spread of insecticide resistance has been reported in all major *Anopheles* mosquito species across malaria-endemic areas ^{2–6}. Similarly, with the increased treatment of malaria cases, recent emergence of *Plasmodium falciparum* resistance against ACTs has been noted ⁷, threatening malaria control and elimination efforts. *Plasmodium falciparum* remains the most widespread *Plasmodium* species across tropical regions of the world, causing the highest malaria morbidity and mortality rates ⁸. During their asexual intraerythrocytic developmental cycle (IDC) in the human host, *P. falciparum* parasites invade the red blood cells (RBCs) resulting in the occurrence of malaria symptoms. Thereafter, some asexual parasites form gametocytes, the sexually-differentiated transmission stages. Following feeding on gametocyte-infected human blood, *Anopheles gambiae* mosquitoes can become infected and transmit malaria parasites after biting another host ^{9,10}. Studies have reported that carriers of subpatent *Plasmodium falciparum* might have future periods of increased parasite density ^{11,12}. These low-density infections have been shown to contribute to and sustain malaria transmission in endemic settings ¹³. The transmissible stage (gametocyte) of *Plasmodium* parasite has now become an attractive target for malaria elimination using either gametocytocidal drugs ^{14,15} or vaccines against the sporogonic stages of the parasite within mosquito vectors ^{16,17}.

To better protect their citizens from malaria, the African Union, in partnership with the Roll Back Malaria (RBM), launched a continent-wide campaign in July 2018 called "Zero malaria starts with me" ¹⁸.

Additionally, a new initiative called "Civil Society for Malaria Elimination (CS4ME)" from civil society organisations was launched in 2018. This coalition aims to encourage grassroots movements in malaria control initiatives and ensure that decision-making is inclusive for those communities most affected by this fatal disease¹⁹. Community engagement is key to malaria elimination but requires that the research community continues to develop effective control technologies. Blocking the transmission of *Plasmodium* parasite from humans to *Anopheles* vectors remains a promising strategy for malaria control and elimination^{10,20,21}. In order to evaluate this strategy, *in vitro* transmission-blocking studies targeting gametocyte-stage parasites have been developed. However, these studies are often difficult to perform in the laboratory; particularly in malaria endemic countries. This is due to the difficulty of viable (capable of infecting mosquitoes) *in vitro* gametocyte production^{22,23}. This underlines the need for promoting experimental feeding assays for cryopreservation of *Plasmodium* gametocytes to strengthen malaria transmission-blocking assays.

Studies on the transmission of malaria parasites are commonly restricted to a few *P. falciparum* reference laboratory strains maintained in *in vitro* culture for decades^{24,25}. The unavailability of viable cultured gametocytes, coupled with financial and ethical issues raised by the recruitment of gametocyte carriers, and variations in the infectivity of gametocytes from different carriers²⁶ hamper the establishment of these experiments in several malaria endemic areas especially sub-Saharan Africa. Moreover, the use of standard laboratory strains of *P. falciparum* as NF54 for investigating parasite biology may have limited applications in the field because the genetic composition of these laboratory isolates often deviate from their original source²⁷. In addition, it is possible that long-term culturing of *P. falciparum* NF54 strain can lead to genetic changes as observed in some clones of *P. falciparum*²⁸ and therefore, all the NF54 parasite-lines in culture in different laboratories may not be genetically identical. Such changes in the genetic composition of laboratory-adapted *P. falciparum* clones could lead to the appearance of differences in transcriptomes²⁷ that could directly influence the interactions of parasites with their vectors. Recently, there has been a drive to use fresh culture-adapted *P. falciparum* field isolates (which are genotypically and phenotypically close to those in the field) for antimalarial drug screening rather than long-term laboratory strains which are heavily selected for *in vitro* growth^{29–31}. It is also important not to use only freshly collected *P. falciparum* gametocyte-positive blood samples from patients to study parasite-vector interactions for malaria transmission-blocking assays given that, the samples are usually not enough to perform multiple assays, which make it hard to distinguish between technical and biological sources of variation in infectivity experiments.

In this study, we implemented *in vitro* continuous culturing of *P. falciparum* field isolates freshly collected from a malaria-infected individual until gametocytogenesis as well as the laboratory-standard reference strain NF54. We compared the dynamics of the IDC and the propensity to generate gametocytes between the parasite strains. Further, we evaluated the infectivity to *An. gambiae* of gametocytes from the field isolates compared to that of NF54 through standard membrane feeding assays. Finally, we determined mosquito infectivity of cryopreserved gametocytes from the culture-adapted field isolates.

Results

P. falciparum NF54 and field isolates in routine culture and gametocytogenesis

Both *P. falciparum* strains showed similar IDC through merozoite, ring, trophozoite and schizont parasite stages. During the 12 days of *in vitro* culture, an increase in blood-stage parasitaemia was recorded in both *P. falciparum* strains (ranging from 0.035 to 10.5% for NF54 and 0.02 to 11.53% for Ben229, $p = 0.57$) (Fig. 1). On day 14 post-thawing, Ben229 displayed significantly higher V-stage mature gametocytaemia (1.8%) compared to that of *P. falciparum* NF54 (0.9%) ($p = 0.003$) as illustrated in Fig. 2a.

Infectivity to *An. gambiae* of *P. falciparum* NF54 and field isolates

Mature gametocytes were generated from both NF54 and Ben229 strains. Abilities of male gametocytes to exflagellate were similar ($p = 0.15$) in both *P. falciparum* strains (Fig. 2b). The NF54 gametocytes only infected 3 of the 8 *An. gambiae* strains used with mean oocyst prevalence varying from 3.9 to 21.7% and a median intensity of 1 oocyst/midgut (Figs. 3a, b). In contrast, the culture-adapted *P. falciparum* field isolates (Ben229) infected all 8 *An. gambiae* strains with a mean oocyst prevalence ranging from 9.7 to 40.5% and a median oocyst intensity up to 6 oocysts/infected mosquito midgut (Figs. 3c, d). The pyrethroid-resistant *An. gambiae* s.s. KisKdr strain exhibited the highest mean oocyst prevalence (40%) and median oocyst intensity (6 oocysts/midgut) with Ben229 (Figs. 3c, d). When mosquito specimens from all strains were pooled, the mean oocyst prevalence and intensity of Ben229 were significantly higher (16.94%, $CI_{95\%} = [15.15-18.73]$, $p < 0.0001$ and 3 oocysts/infected mosquito midgut, $p = 0.002$) compared to those of NF54 (3.13%, $CI_{95\%} = [2.30-3.96]$ and 1 oocyst/infected mosquito midgut) (Figs. 3e, f). The images presented in Fig. 4 show the morphologies of asexual, gametocyte and oocyst stages of *P. falciparum* Ben229.

Viability and infectiousness of cryopreserved gametocytes from field isolates

Interestingly, we observed that mature stage-V gametocytes of Ben229 remained viable (morphologically) and stable (in term of density) over 2 weeks of cryopreservation. Overall, no difference was observed between pre- and post-cryopreservation gametocytaemias for any of the four gametocyte culture replicates (Fig. 5a). Two of the strains of *An. gambiae* (KisKdr and TSB) were used to evaluate infectiousness of post-cryopreserved gametocytes; chosen because they displayed the highest permissiveness to infection (in terms of oocyst prevalence recorded in the first experiments). After thawing, both *An. gambiae* strains were infected with mean oocyst prevalence ranging from 6.25 to 30% and median oocyst intensity varying from 3 to 12 oocysts/midgut (Figs. 5b, c, d).

Discussion

Effective malaria control relies on several approaches including transmission-blocking strategies. However, few studies have been performed to evaluate these strategies by using near-field isolates of *P.*

falciparum. In the present work, we compared the intraerythrocytic developmental cycle (parasitaemias) over time, and infectivity to *An. gambiae* of culture-adapted field isolates to those of a reference laboratory *P. falciparum* strain NF54. *Plasmodium falciparum* field isolates (Ben229) parasitaemias were similar to those of NF54 over time, indicating that the field isolates seemed to have normal phenotypic characteristics with regard to their growth and maintenance under standard *P. falciparum* continuous culture conditions. Other studies reported phenotypic stability and subsequent red blood cell invasion in culture-adapted *P. falciparum* field isolates from Kenya, China-Myanmar and South America^{32–34}. In addition, our findings indicate that both of the *P. falciparum* strains produced functionally mature gametocytes which successfully exflagellated, although the Ben229 strain generated substantially higher mature stage V gametocytaemias. Thus, the culture-adapted Ben229 strain could be more suitable for the screening of vaccines and drugs against asexual and sexual blood stages of *P. falciparum*.

For malaria elimination in endemic countries, one of the most promising measures remains the blocking of transmission of *Plasmodium* from human host to *Anopheles* mosquito³⁵ since the passage through the malaria vector is a fundamental step of parasite life cycle¹⁰. Laboratory reference *P. falciparum* strains such as NF54 and 3D7 are still commonly used in *Plasmodium* transmission-blocking assays^{20,36,37}. Carrying out such studies using freshly culture-adapted field isolates could provide more realistic parameters reflecting malaria transmission as occurring in natural settings. By comparing the overall mosquito infection success (prevalence and intensity of oocyst infection), we observed a higher infectivity of *P. falciparum* Ben229 to both laboratory and near-field *An. gambiae* compared to that of NF54. Since both parasite strains were cultured in the same conditions and used for the feeding assays in one hand, and they displayed similar number of exflagellation centers on another hand, the difference of infectivity observed may, in part, be explained by the differences in the Ben229 performance to develop in these mosquito strains. This superior performance developed by Ben229 in infecting malaria vectors could be related to the several gametocyte features such as biology, physiology, genotype, behaviour, plasticity, sex ratio and mating patterns that favoured their infectivity to mosquitoes. Morlais and colleagues³⁸ demonstrated that, during their within-mosquito development, *P. falciparum* field isolates use various strategies to reproduce according to the parasite genotypes. They found that genetic polymorphism in the parasite diploid stages positively correlated to the oocyst loads in infected mosquitoes. In addition, other studies reported that, a gene in laboratory *P. falciparum* strain NF54 allowed parasites to evade the immune system of *An. gambiae* mosquitoes favouring their within-mosquito development^{39,40}. Since the *P. falciparum* field isolates Ben229 has been freshly adapted to culture in 2018, it would have maintained a genetic polymorphism that allowed them to reproduce more successfully in mosquito vectors than long-term laboratory NF54 parasites. We plan to explore in further studies, the genetic factors that conferred the observed enhanced performance of *P. falciparum* Ben229.

A model-based evaluation of intervention strategies demonstrated that existing tools and the unrealistic deployment of current control strategies are unlikely to achieve the goal of reducing malaria transmission in most African settings⁴¹. This finding has highlighted the need for additional and new tools and strategies that specifically target malaria transmission by reducing the vectorial capacities of

the main malaria vectors in sub-Saharan Africa³⁵. Among these tools/strategies, vaccines that interrupt malaria transmission (VIMT) could be a crucial strategy which will considerably contribute to the effort to eradicate malaria in African settings⁴². Progress has been made in development of transmission-blocking vaccines (TBVs) that have shown promising safety and functional activity during clinical assays^{43–45}. Once the candidate antigens that prevent the onward transmission of malaria parasite to its vector are discovered, both direct and standard membrane feeding assays are used to assess their efficacy^{46,47}.

The evaluation of the candidate antigens for TBV discovery faces a number of peculiar challenges that related to the type of parasite and mosquito colony, the parasite exposure and the availability of viable gametocytes⁴⁸. In the aim to predict the efficacy of these candidate antigens in natural settings, field circulating parasites and local mosquito colonies would have to be the experiment materials. Moreover, the level of parasite exposure (relies primarily on gametocytes density in the infected blood) would need to be mastered technically. The result obtained in the present work overcomes this requirement and will allow different candidate antigens to be evaluated using naturally occurring parasites isolates with local mosquito colonies in African settings where the availability of viable cryopreserved gamatocytes has become possible. We report that cryopreserved V-stage mature gametocytes of *P. falciparum* field isolates (Ben229) maintained in gassed tissue culture flasks, remained stable (in terms of density) and infectious to both laboratory and near-field *Anopheles gambiae* mosquitoes after been cryopreserved. Furthermore, mosquito infectivity level produced was almost similar to that of the fresh-produced gametocytes. Cryopreserved Ben229 gametocytes could help to strenghten the production of infectious *P. falciparum* gametocytes which could boost inter laboratory replication studies in malaria endemic regions because they can be transported in liquid nitrogen to other laboratories.

So far, technical platforms for successful *P. falciparum* gametocyte culture followed by experimental infections are lacking in Africa. Empirically, the *P. falciparum* strains such as NF54 and 3D7 are the parasite lines most available and used for *in vitro* routine culture in some African laboratories^{49–51}. But production of infectious gametocyte from these parasite strains for experimental infections of mosquitoes is still an arduous task. The present work proposes the *P. falciparum* field isolates (Ben229) collected and adapted in *in vitro* routine culture in Benin (West Africa) showed the higher performances in terms of gametocyte generation and infectivity to malaria vector *An. gambiae* over NF54 line. This provides a glimmer of hope for promoting these field isolates of *P. falciparum* and therefore, facilitate expansion of the platforms for experimental infections in malaria-endemic countries. Thus, Ben229 could be an interesting asset for evaluation of the VIMT candidates in endemic zones through membrane feeding assays.

Plasmodium falciparum field isolates adaptation in *in vitro* culture for infectious gametocytes production could undoubtedly improve cellular studies towards effective malaria control and elimination. The present work highlights infectivity to *An. gambiae* of the fresh-produced and cryopreserved V-stage mature gametocytes from freshly culture-adapted *P. falciparum* field isolates. Further studies are required to (i) explore the genomic profile of *P. falciparum* Ben229, (ii) expand the number of field isolates and (iii)

investigate how long the infection capacity of V-stage mature gametocytes from culture-adapted field isolates will be maintained during cryopreservation.

Methods

Plasmodium falciparum NF54 and field isolates in vitro continuous culture

In this study, we used two *P. falciparum* strains (laboratory line NF54 isolated from Netherlands in 1981^{24,25} and field isolates (encoded Ben229) collected in Benin in 2018. The NF54 strain was obtained from MR4, BEI Resources, USA. The *P. falciparum* field isolates Ben229 were collected from a symptomatic patient in the framework of a cross-sectional study we have conducted in 2018 among school children aged ≥ 4 years in Ouidah, South-western Benin.

In vitro culturing of both NF54 and the field isolates strains was implemented following standard protocols with minor modifications^{52,53}. Briefly, after centrifugation of 3–4 mL of blood, at 800 g for 5 minutes, plasma was removed and the pellets washed and then adjusted to 5% haematocrit with RPMI-1640 (with 2 mM L-glutamine, 25 mM HEPES, 0.85 g/L Sodium bicarbonate) supplemented with 50 mg/L Hypoxanthine (Gibco), 0.25% (w/v) Albumax II (Gibco) as human AB⁺ serum substitute^{54–57} without gentamycin. Cell culture flasks (T-75 cm² Nunclon™, Denmark) were used under a reduced oxygen environment of 3% O₂, 5% CO₂ and 92% N₂ (AIR LIQUID France Industrie) and incubated at 37°C. The parasites were maintained in uninterrupted culture with periodic supplement of washed O⁺ RBCs and media, over at least four weeks (culture flasks were changed weekly) and parasitaemias were quantified daily by microscopy based on rapid Giemsa staining of thin smears⁵⁸.

Plasmodium falciparum NF54 and field isolates gametocytogenesis and exflagellation tests

Gametocytes of *P. falciparum* NF54 and field isolates were generated as previously described with slight modifications^{59,60}. Cultures were maintained until approximately 8% of RBCs showed ring-stage parasitaemia before culture synchronization using 5% D-sorbitol (Sigma). Fresh O⁺ RBCs were added to the synchronized cultures, which were maintained below 30°C for up to 30 minutes in order to stimulate gametocyte production. Each culture was kept at 37°C, and the medium was changed daily during formation of the sexual stages until V-stage mature gametocytes were harvested, 14 to 15 days later^{61–63}. All gametocyte developmental stages were monitored daily under a microscope and the V-stages especially were identified and quantified according to previously described method⁶⁴.

To assess the ability of male *P. falciparum* gametocytes to exflagellate, 200 μ L of the gametocyte culture from both *P. falciparum* strains were aliquoted into microfuge tubes and subjected to reduced temperature (30°C) by placing in tap water for 10 minutes according to protocol previously described⁶⁵.

Assessment of mosquito infectivity of NF54 and Ben229 fresh-produced gametocytes

The *P. falciparum* standard membrane feeding assays (SMFA) were performed as described previously ⁶⁶ to explore the infectiousness of both NF54 and Ben229. The different *An. gambiae* strains used, their insecticide resistance profiles are summarized in Table 1. The near-field strains of *An. gambiae* s.l. collected in 2018 were maintained under pressure of the discriminating dose of two insecticides (0.05% deltamethrin and 0.1% bendiocarb) according to WHO test procedures ⁶⁷.

Table 1
Known resistance mutations and phenotypic resistance profiles for each *An. gambiae* strain.

<i>An. gambiae</i> strains	Type of the strains	Known resistance mutations	Resistance profiles	References
Kisumu (Ki)	Laboratory colonies	None	Susceptible for all insecticides	69
KisKdr (Kd)		Homozygous for <i>kdr</i> ^R (L1014F) mutation	Pyrethroids and DDT resistant	70
AcerKis (Ac)		Homozygous for <i>ace-1</i> ^R (G119S) mutation	Carbamates and organophosphates resistant	71
AcerKdrKis (Ak)		Homozygous for both <i>kdr</i> ^R (L1014F) and <i>ace-1</i> ^R (G119S) mutations	Pyrethroids and DDT, carbamates and organophosphates resistant	72
ASD	Near-field strains	Unknown	Deltamethrin resistant	73,74
ASB		Unknown	Bendiocarb resistant	
TSD		Unknown	Deltamethrin resistant	3,75
TSB		Unknown	Bendiocarb resistant	
ASD, Accra selected with deltamethrin; ASB, Accra selected with bendiocarb; TSD, Tiassalé selected with deltamethrin; TSB, Tiassalé selected with bendiocab.				

During SMFA, all materials were pre-warmed and maintained at 37°C to prevent early exflagellation. The NF54 and Ben229 gametocytes from the culture flasks were confirmed to be free for any bacterial contamination by microscopic observations. The mosquitoes used for the feeding experiments were 3 to 4-day old *An. gambiae* females that had been sucrose-starved for 24 hours. Prior to infection, the gametocyte cultures were centrifuged at 700 g for 3 minutes. Pellets were immediately resuspended with AB⁺ heat-inactivated serum to 50% haematocrit and with O⁺ blood to 0.4% gametocytaemia. Mosquitoes were fed on the gametocyte-infected blood up to 20 minutes to allow the majority of them to be fully engorged. After 24 hours, fed mosquitoes were separated and maintained at 27 ± 2°C and 70 ± 8% relative

humidity with access to 10% honey solution until midgut dissection. Each infection experiment was performed three times.

Cryopreservation of Ben229 gametocytes and experimental infections

To assess whether cultured stage V (mature) gametocytes from the *P. falciparum* field isolates could successfully infect *Anopheles* mosquitoes after a round of cryopreservation, a subset of the gametocytes produced was transferred into the vapour phase liquid nitrogen (AIR LIQUID Cryogenic Division, France) according to the standard protocol⁶⁸ with slight modifications. Four gametocyte cultures with different gametocytaemias (encoded respectively GC1 (1.27%), GC2 (0.87%), GC3 (0.73%) and GC4 (1.53%)) were centrifuged separately as described above and supernatants were removed. Pellet volume was estimated and equal volumes of the glycerin-based solution (Sigma) consisting of glycerin, D-sorbitol and NaCl were added and the cell suspension was aliquoted in 2 mL individual cryovials (Nunc™, China). After gentle agitation, the cryovials were rapidly transferred in liquid nitrogen for 14 days.

The procedures described in Keister *et al.*⁶⁸ with minor modifications were used to thaw the cryopreserved gametocytes. The frozen gametocytes were thawed in a 37°C water bath for 1 minute. Following centrifugation at 700 g for 3 minutes, supernatants were removed and the gametocyte cultures were reconstituted with 3.5% NaCl solution. The NaCl solution was removed after centrifugation and a pellet sample obtained from each gametocyte culture was taken to prepare the thin smear and the remaining was suspended in complete medium for 3 hours prior to experimental infections. Giemsa-stained thin smears were examined under light microscopy for morphological evaluation of gametocytes and assessment of their densities before cryopreservation and post thawing. Experimental infections using both a laboratory colony (KisKdr) and a near-field strain (Tiassalé selected with bendiocarb) of *An. gambiae* were performed three times as described above.

Oocyst counting

The midguts of blood-fed mosquito females were dissected in 0.05% mercurochrome on 7th day following experimental infections. Intensity of malaria parasite infection in each individual female was assessed by counting oocysts under a light microscope.

Statistical Analysis

All data analysis was carried out using GraphPad Prism version 8.02 (San Diego, California USA). Parasite (asexual stages and gametocytes) densities were determined by counting the parasitized RBCs from examination of at least 20,000 RBCs and expressed as percentages. The number of exflagellation centers observed per field was used as the ability of male gametocytes to exflagellate. Oocyst prevalence was defined as the number of mosquitoes presenting at least one oocyst in their midguts divided by the total number of dissected mosquitoes. Oocyst intensity is the average number of oocysts developed by infected individual mosquitoes. To determine significance of the difference in parameters such as dynamics of parasitaemias, stage V gametocytaemia, exflagellation ability of male gametocytes and

infectivity (oocyst prevalence and intensity) between NF54 and Ben229, we used Mann-Whitney tests with $p < 0.05$ accepted as statistically significant.

Availability of data and materials

The datasets are available from the corresponding author on reasonable request.

Declarations

Acknowledgements

We would like to thank the clinical technicians who help to have field collected *P. falciparum* samples; Gabriel Houssou, Roseline Dagba and Mélanie Kpohlo from health centre of Kindji (Ouidah, Benin). We are grateful to MR4, BEI Resources, USA for the provision of MRA-1001, the NF54 *P. falciparum* parasite strain used in this study.

Author contributions

A.A.M., L.S.D., D.W. and M.J.D. conceived and designed the study. A.A.M., L.S.D., F.K.A. and L.D. performed the experiments. A.A.M. and L.S.D. analysed the data. A.A.M., L.S.D., L.E.A., E.M.O., D.W. and M.J.D. drafted the manuscript. All authors read and approved the final version of manuscript.

Additional information

Competing interests: The authors declare that they have no competing interests.

Funding

This study was supported by grant to LSD from Wellcome Trust (intermediate fellowship in public health and tropical medicine n° 109917/Z/15/Z). The funding body had no role in the study design, analysis and interpretation of data, writing of the manuscript and in decision to publish.

References

1. Bhatt, S. *et al.* The effect of malaria control on *Plasmodium falciparum* in Africa between 2000 and 2015. *Nature*.**526**, 207–211 (2015).
2. N'Guessan, R. *et al.* Resistance to carbosulfan in *Anopheles gambiae* from Ivory Coast, based on reduced sensitivity of acetylcholinesterase. *Medical and Veterinary Entomology*.**17**, 19–25 (2003).
3. Ahoua Alou, L. P. *et al.* Distribution of ace-1R and resistance to carbamates and organophosphates in *Anopheles gambiae* s.s. populations from Côte d'Ivoire. *Malar. J.***9**, 167 (2010).
4. Ranson, H. *et al.* Pyrethroid resistance in African anopheline mosquitoes: what are the implications for malaria control? *Trends in Parasitology*.**27**, 91–98 (2011).

5. Corbel, V., N'Guessan, R. & Distribution Mechanisms, Impact and Management of Insecticide Resistance in Malaria Vectors: A Pragmatic Review. *Anopheles mosquitoes - New insights into malaria vectors* (ed. S Manguin), pp. 579–633. (2013).
6. Ranson, H. & Lissenden, N. Insecticide Resistance in African Anopheles Mosquitoes: A Worsening Situation that Needs Urgent Action to Maintain Malaria Control. *Trends in Parasitology*.**32**, 187–196 (2016).
7. Ashley, E. A. *et al.* Spread of Artemisinin Resistance in Plasmodium falciparum Malaria. *New England Journal of Medicine*.**371**, 411–423 (2014).
8. WHO. *World Malaria Report 2017*. World Health Organization, Geneva, Switzerland. (2018).
9. Baker, D. A. Malaria gametocytogenesis. *Molecular and Biochemical Parasitology*.**172**, 57–65 (2010).
10. Bousema, T. & Drakeley, C. Epidemiology and Infectivity of Plasmodium falciparum and Plasmodium vivax Gametocytes in Relation to Malaria Control and Elimination. *Clin. Microbiol. Rev.***24**, 377–410 (2011).
11. Ashley, E. A. & White, N. J. The duration of Plasmodium falciparum infections. *Malar. J.***13**, 500 (2014).
12. Bretscher, M. T. *et al.* The distribution of Plasmodium falciparum infection durations. *Epidemics*.**3**, 109–118 (2011).
13. Slater, H. C. *et al.* The temporal dynamics and infectiousness of subpatent Plasmodium falciparum infections in relation to parasite density. *Nature Communications*.**10**, 1433 (2019).
14. Dechering, K. J. *et al.* Modelling mosquito infection at natural parasite densities identifies drugs targeting EF2, PI4K or ATP4 as key candidates for interrupting malaria transmission. *Sci. Rep.***7**, 17680 (2017).
15. Dicko, A. *et al.* Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. *Lancet. Infect. Dis.***16**, 674–684 (2016).
16. Da, D. F. *et al.* Experimental study of the relationship between Plasmodium gametocyte density and infection success in mosquitoes; implications for the evaluation of malaria transmission-reducing interventions. *Exp. Parasitol.***149**, 74–83 (2015).
17. Coelho, C. H., Rappuoli, R., Hotez, P. J. & Duffy, P. E. Transmission-Blocking Vaccines for Malaria: Time to Talk about Vaccine Introduction. *Trends in Parasitology*.**35**, 483–486 (2019).
18. Zero Malaria Starts with Me.RBM Partnership to End Malaria and the African Union Commission;
19. 1st Malaria World Congress 2018. Global Civil Society for Malaria Elimination (CS4ME) | Tropical Health Matters.
20. Paton, D. G. *et al.* Exposing Anopheles mosquitoes to antimalarials blocks Plasmodium parasite transmission. *Nature*.**567**, 239–243 (2019).
21. Romoli, O. & Gendrin, M. The tripartite interactions between the mosquito, its microbiota and Plasmodium. *Parasites & Vectors*.**11**, 200 (2018).

22. Ponnudurai, T., Meuwissen, J. H. E., Th., Leeuwenberg, A. D. E. M., Verhave, J. P. & Lensen, A. H. W. The production of mature gametocytes of *Plasmodium falciparum* in continuous cultures of different isolates infective to mosquitoes. *Transactions of the Royal Society of Tropical Medicine and Hygiene*.**76**, 242–250 (1982).
23. Blagborough, A. M. *et al.* Assessing Transmission Blockade in *Plasmodium* spp. in *Malaria: Methods and Protocols* (ed. Ménard, R.) 577–600 (Humana Press, 2013). doi:10.1007/978-1-62703-026-7_40.
24. Ponnudurai, T., Leeuwenberg, A. D. E. M. & Meuwissen, J. H. E. T. Chloroquine sensitivity of isolates of *Plasmodium falciparum* adapted to in vitro culture. *Tropical and Geographical Medicine*.**33**, 50–54 (1981).
25. De Delemarre-van, H. A. & De Waal, F. C. A second patient with *Plasmodium falciparum* malaria contracted naturally in the Netherlands. *Nederlands Tijdschrift voor Geneeskunde*.**125**, 375–377 (1981).
26. Drakeley, C. J. *et al.* Transmission-blocking effects of sera from malaria-exposed individuals on *Plasmodium falciparum* isolates from gametocyte carriers. *Parasitology*.**116**, 417–423 (1998).
27. Mackinnon, M. J. *et al.* Comparative Transcriptional and Genomic Analysis of *Plasmodium falciparum* Field Isolates. *PLOS Pathogens*.**5**, e1000644 (2009).
28. Moser, K. A. *et al.* Strains used in whole organism *Plasmodium falciparum* vaccine trials differ in genome structure, sequence, and immunogenic potential. *Genome Med*.**12**, 6 (2020).
29. Leba, L. J. *et al.* Use of *Plasmodium falciparum* culture-adapted field isolates for in vitro exflagellation-blocking assay. *Malar. J.***14**, 234 (2015).
30. Wadi, I. *et al.* Methylene blue induced morphological deformations in *Plasmodium falciparum* gametocytes: implications for transmission-blocking. *Malar. J.***17**, 11 (2018).
31. Kreidenweiss, A., Kremsner, P. G. & Mordmüller, B. Comprehensive study of proteasome inhibitors against *Plasmodium falciparum* laboratory strains and field isolates from Gabon. *Malar J.***7**, 187 (2008).
32. Lopez-Perez, M. *et al.* *Plasmodium falciparum* Field Isolates from South America Use an Atypical Red Blood Cell Invasion Pathway Associated with Invasion Ligand Polymorphisms. *PLOS ONE*.**7**, e47913 (2012).
33. Yeda, R. *et al.* The Genotypic and Phenotypic Stability of *Plasmodium falciparum* Field Isolates in Continuous In Vitro Culture. *PLOS ONE*.**11**, e0143565 (2016).
34. Zhang, Q. *et al.* From In Vivo to In Vitro: Dynamic Analysis of *Plasmodium falciparum* var Gene Expression Patterns of Patient Isolates during Adaptation to Culture. *PLOS ONE* **6**, e20591(2011).
35. Alonso, P. L. *et al.* A Research Agenda to Underpin Malaria Eradication. *PLOS Medicine*.**8**, e1000406 (2011).
36. Ferrer, P., Vega-Rodriguez, J., Tripathi, A. K., Jacobs-Lorena, M. & Sullivan, D. J. Antimalarial Iron Chelator FBS0701 Blocks Transmission by *Plasmodium falciparum* Gametocyte Activation Inhibition. *Antimicrobial Agents and Chemotherapy*.**59**, 1418–1426 (2015).

37. Colmenarejo, G. *et al.* Predicting transmission blocking potential of anti-malarial compounds in the Mosquito Feeding Assay using Plasmodium falciparum Male Gamete Inhibition Assay. *Sci Rep.***8**, 1–13 (2018).
38. Morlais, I. *et al.* Plasmodium falciparum Mating Patterns and Mosquito Infectivity of Natural Isolates of Gametocytes. *PLOS ONE*.**10**, e0123777 (2015).
39. Molina-Cruz, A. *et al.* The Human Malaria Parasite Pfs47 Gene Mediates Evasion of the Mosquito Immune System. *Science*.**340**, 984–987 (2013).
40. Molina-Cruz, A. *et al.* Plasmodium evasion of mosquito immunity and global malaria transmission: The lock-and-key theory. *PNAS*.**112**, 15178–15183 (2015).
41. Griffin, J. T. *et al.* Reducing Plasmodium falciparum Malaria Transmission in Africa: A Model-Based Evaluation of Intervention Strategies. *PLOS Medicine*.**7**, e1000324 (2010).
42. Vaccines, T. & malERA, C. G. on. A Research Agenda for Malaria Eradication: Vaccines. *PLOS Medicine*.**8**, e1000398 (2011).
43. Talaat, K. R. *et al.* Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults. *PLOS ONE*.**11**, e0163144 (2016).
44. Sagara, I. *et al.* Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults. *Lancet. Infect. Dis.***18**, 969–982 (2018).
45. Sauerwein, R. W. & Bousema, T. Transmission blocking malaria vaccines: Assays and candidates in clinical development. *Vaccine*.**33**, 7476–7482 (2015).
46. Ponnudurai, T., van Gemert, G. J., Bensink, T., Lensen, A. H. W. & Meuwissen, J. H. E. Th. Transmission blockade of Plasmodium falciparum: its variability with gametocyte numbers and concentration of antibody. *Transactions of the Royal Society of Tropical Medicine and Hygiene*.**81**, 491–493 (1987).
47. Bompard, A. *et al.* Evaluation of two lead malaria transmission blocking vaccine candidate antibodies in natural parasite-vector combinations. *Sci. Rep.***7**, 6766 (2017).
48. Wu, Y., Sinden, R. E., Churcher, T. S., Tsuboi, T. & Yusibov, V. Chapter Three - Development of Malaria Transmission-Blocking Vaccines: From Concept to Product. in *Advances in Parasitology* (eds. Rollinson, D. & Stothard, J. R.) vol. 89 109–152(Academic Press, 2015).
49. Cudjoe, E., Donu, D., Okonu, R. E., Amponsah, J. A. & Amoah, L. E. The In Vitro Antiplasmodial Activities of Aqueous Extracts of Selected Ghanaian Herbal Plants. *Journal of Parasitology Research* vol 2020 e5041919 <https://www.hindawi.com/journals/jpr/2020/5041919/> (2020).
50. Awandare, G. A., Nyarko, P. B., Aniweh, Y., Ayivor-Djanie, R. & Stoute, J. A. Plasmodium falciparum strains spontaneously switch invasion phenotype in suspension culture. *Sci. Rep.***8**, 5782 (2018).
51. Penali, L., Mulholland, D. A., Tano, K. D., Cheplogoi, P. K. & Randrianarivelojosia, M. Low antiplasmodial activity of alkaloids and amides from the stem bark of Zanthoxylum rubescens (Rutaceae). *Parasite*.**14**, 161–164 (2007).

52. Trager, W. & Jensen, J. B. Human malaria parasites in continuous culture. *Science*.**193**, 673–675 (1976).
53. Witkowski, B. *et al.* Reduced Artemisinin Susceptibility of *Plasmodium falciparum* Ring Stages in Western Cambodia. *Antimicrobial Agents and Chemotherapy*.**57**, 914–923 (2013).
54. Srivastava, K., Singh, S., Singh, P. & Puri, S. K. In vitro cultivation of *Plasmodium falciparum*: Studies with modified medium supplemented with ALBUMAX II and various animal sera. *Exp. Parasitol.***116**, 171–174 (2007).
55. Cranmer, S. L., Magowan, C., Liang, J., Coppel, R. L. & Cooke, B. M. An alternative to serum for cultivation of *Plasmodium falciparum* in vitro. *Transactions of the Royal Society of Tropical Medicine and Hygiene*.**91**, 363–365 (1997).
56. Kwansa-Bentum, B. *et al.* Comparative studies of serum-free media and detection techniques for in vitro drug sensitivity assessment of *Plasmodium falciparum*. *Open Journal of Clinical Diagnostics*.**3**, 115–121 (2013).
57. Asahi, H. *Plasmodium falciparum*: Chemically defined medium for continuous intraerythrocytic growth using lipids and recombinant albumin. *Exp. Parasitol.***121**, 22–28 (2009).
58. Moody, A. Rapid Diagnostic Tests for Malaria Parasites. *Clin. Microbiol. Rev.***15**, 66–78 (2002).
59. Saliba, K. S. & Jacobs-Lorena, M. Production of *Plasmodium falciparum* Gametocytes In Vitro. in *Malaria: Methods and Protocols* (ed. Ménard, R.) 17–25 (Humana Press, 2013). doi:10.1007/978-1-62703-026-7_2.
60. Trager, W. & Gill, G. S. Enhanced Gametocyte Formation in Young Erythrocytes by *Plasmodium falciparum* In Vitro. *The Journal of Protozoology*.**39**, 429–432 (1992).
61. Ifediba, T. & Vanderberg, J. P. Complete in vitro maturation of *Plasmodium falciparum* gametocytes. *Nature*.**294**, 364–366 (1981).
62. Ponnudurai, T., Lensen, A. H. W., Leeuwenberg, A. D. E. M. & Meuwissen, J. H. E. Th. Cultivation of fertile *Plasmodium falciparum* gametocytes in semi-automated systems. 1. Static cultures. *Transactions of the Royal Society of Tropical Medicine and Hygiene*.**76**, 812–818 (1982).
63. Delves, M. J. *et al.* Routine in vitro culture of *P. falciparum* gametocytes to evaluate novel transmission-blocking interventions. *Nat Protoc.***11**, 1668–1680 (2016).
64. Carter, R. & Miller, L. H. Evidence for environmental modulation of gametocytogenesis in *Plasmodium falciparum* in continuous culture. *Bull World Health Organ.***57** (Suppl 1), 37–52 (1979).
65. Ogwan'g, R. A. *et al.* Factors Affecting Exflagellation of in Vitro-Cultivated *Plasmodium falciparum* Gametocytes. *The American Journal of Tropical Medicine and Hygiene*.**49**, 25–29 (1993).
66. Bharti, A. R. *et al.* Experimental infection of the neotropical malaria vector *Anopheles darlingi* by human patient-derived *Plasmodium vivax* in the peruvian Amazon. *The American Journal of Tropical Medicine and Hygiene*.**75**, 610–616 (2006).
67. WHO. 'Geneva: World malaria Report' 2016, World Health Organization, Test Procedures for Insecticide Resistance Monitoring in Malaria Vector Mosquitoes, Geneva, Swizeland 2nd edition,

2016. (2016).
68. Keister, D. B. & Kaslow, D. C. Cryopreservation of *Plasmodium falciparum* Gametocytes. *Exp. Parasitol.***78**, 118–119 (1994).
69. Shute, G. T. A Method of Maintaining Colonies of East African Strains of *Anopheles gambiae*. *Annals of Tropical Medicine & Parasitology***50**, 92–94 (1956).
70. Alout, H. *et al.* Insecticide Resistance Alleles Affect Vector Competence of *Anopheles gambiae* s.s. for *Plasmodium falciparum* Field Isolates. *PLOS ONE***8**, e63849 (2013).
71. Djogbénou, L. *et al.* Characterization of Insensitive Acetylcholinesterase (ace-1R) in *Anopheles gambiae* (Diptera: Culicidae): Resistance Levels and Dominance. *ment* **44**, 805–810(2007).
72. Assogba, B. S. *et al.* Phenotypic effects of concomitant insensitive acetylcholinesterase (ace-1R) and knockdown resistance (kdrR) in *Anopheles gambiae*: a hindrance for insecticide resistance management for malaria vector control. *Parasites & Vectors***7**, 548 (2014).
73. Yawson, A. E., McCall, P. J., Wilson, M. D. & Donnelly, M. J. Species abundance and insecticide resistance of *Anopheles gambiae* in selected areas of Ghana and Burkina Faso. *Medical and Veterinary Entomology***18**, 372–377 (2004).
74. Mitchell, S. N. *et al.* Identification and validation of a gene causing cross-resistance between insecticide classes in *Anopheles gambiae* from Ghana. *PNAS***109**, 6147–6152 (2012).
75. Chouaibou, M. S. *et al.* Increase in susceptibility to insecticides with aging of wild *Anopheles gambiae* mosquitoes from Côte d'Ivoire. *BMC Infectious Diseases***12**, 214 (2012).

Figures




Figure 1. Comparative dynamics of *P. falciparum* Ben229 and NF54 parasitaemias. All asexual parasite stage parasitaemias were calculated across three separate *in vitro* cultures during twelve days. Red arrows indicate culture dilution with fresh O⁺ uninfected red blood cells when high parasitaemias were reached.

Figure 1

Caption found in figure.




Figure 2. Densities and exflagellation ability of *P. falciparum* Ben229 gametocytes compared to those of NF54. a): V-stage mature gametocytaemias obtained during the three experiments. b): Exflagellation tests. Exflagellations/field means the mean number of exflagellation centers observed per field among the three experiments. ** indicates a significant difference between means ($p = 0.003$); ns indicates no significance difference ($p = 0.15$).

Figure 2

Caption found in figure.




Figure 3. Infectivity to *An. gambiae* mosquitoes of fresh-produced gametocytes from *P. falciparum* Ben229 compared to that of NF54. Panels a), c), e) and panels b), d), f) show the mean prevalence of infections and oocyst intensity, respectively, across three feeding assays for *P. falciparum* NF54 or Ben229. In all plots, means and 95% confidence intervals are shown; in the intensity plots (b, d and f), points are offset horizontally where overlapping. Mann–whitney procedure was used to test significance. ** and *** indicate respectively $p=0.002$; $p<0.0001$. Total number of mosquitoes dissected for NF54 infection ($N_{Ki}=204$, $N_{Kd}=132$, $N_{Ac}=120$, $N_{Ak}=132$, $N_{ASD}=204$, $N_{ASB}=288$, $N_{TSD}=297$, $N_{TSB}=318$). Total number of mosquitoes dissected for Ben229 infection ($N_{Ki}=194$, $N_{Kd}=162$, $N_{Ac}=129$, $N_{Ak}=141$, $N_{ASD}=195$, $N_{ASB}=276$, $N_{TSD}=267$, $N_{TSB}=324$). Ki, Kisumu; Kd, KisKdr; Ac, AcerKis; Ad, AcerKdrKis; ASD, Accra selected with deltamethrin; ASB, Accra selected with bendiocarb; TSD, Tiassalé selected with deltamethrin; TSB, Tiassalé selected with bendiocarb.

Figure 3

Caption found in figure.




Figure 4. Morphological appearance of the culture-adapted *P. falciparum* Ben229, through different developmental stages. Panels a, b and c show respectively the erythrocytic stage trophozoites, the V-stage mature gametocytes, and oocysts in an infected *An. gambiae* midgut. Yellow arrows indicate a parasitised erythrocyte in panel a) and an oocyst in panel c). In panel b), the black and green arrows indicate V-stage mature male and female gametocytes respectively.

Figure 4

Caption found in figure.




Figure 5. Viability and infectivity to *An. gambiae* of cryopreserved Ben229 gametocytes. a) shows the comparison between *P. falciparum* Ben229 gametocytaemias before and after cryopreservation. b) illustrates the mean prevalence of infections and panels c, d) present oocyst intensities for the 4 gametocyte cultures among three assays. GC1, GC2, GC3 and GC4 represent respectively the four gametocyte cultures; Kd and TSB represent, respectively, the *An. gambiae* laboratory mosquito strain KisKdr and the near-field bendiocarb-selected Tiassalé strain used. In all plots, means and 95% confidence intervals are shown, with overlapping points offset horizontally in c, d. Total number of mosquitoes dissected: $N_{Kd} = 57$, $N_{TSB} = 96$ for GC1; $N_{Kd} = 113$, $N_{TSB} = 96$ for GC2; $N_{Kd} = 124$, $N_{TSB} = 96$ for GC3; $N_{Kd} = 120$, $N_{TSB} = 96$ for GC4.

Figure 5

Caption found in figure.